This is due to the fact that bortezomib promotes the formation of Beclin-1/PI3KC3 complex and activates autophagy in ALL cells, which ultimately leads to a decrease in the toxic effect of bortezomib on ALL cells (Wang et al., 2015). The gene discussed is BECN1; the disease is acute lymphoblastic leukemia.